Antonio Carlos Wolff MD FACP, FASCO (He/Him)

Oncology•Baltimore, MD

Breast Cancer, Cancer Genetics/Cancer Risk Assessment

Professor of Oncology Co-Director, Breast & Gyn Cancer Program

Join to View Full Profile

201 N BroadwayViragh 10-289Baltimore, MD 21287
Phone+1 410-614-4192

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1992 - 1995
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1991 - 1992
Faculdade de Medicina da Universidade Federal do Rio de JaneiroClass of 1986

Certifications & Licensure

MD State Medical License 1990 - 2027
GA State Medical License 1995 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Fellow (FASCO) American Society of Clinical Oncologists, 2010
Fellow (FACP) American College of Physicians, 2004
Join now to see all

Clinical Trials

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer Start of enrollment: 1996 Jul 01
Terminated
Phase 3
Benzoylphenylurea in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 Mar 01
Completed
Phase 1
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 3
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2003 Dec 01
Completed
Phase 1
Capecitabine in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
ACTIVE_NOT_RECRUITING
PHASE3
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer Start of enrollment: 2007 Jan 01
Completed
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Feb 08
COMPLETED
PHASE3
Pre-Operative Radiation and Veliparib for Breast Cancer Start of enrollment: 2013 Jul 22
Completed
Phase 1
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
ACTIVE_NOT_RECRUITING
PHASE3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
ACTIVE_NOT_RECRUITING
PHASE2
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Terminated
Phase 1, Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Start of enrollment: 2014 Jan 16
ACTIVE_NOT_RECRUITING
NA
Johns Hopkins Breast Cancer Program Longitudinal Repository
ACTIVE_NOT_RECRUITING
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Start of enrollment: 2013 Dec 13
Terminated
Phase 2
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) Start of enrollment: 2017 Feb 20
Active, not recruiting
Not Applicable
Involving Family to Improve Communication in Breast Cancer Care Start of enrollment: 2017 Jul 20
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
Guillermo Villacampa, Tomás Pascual, Paolo Tarantino, Javier Cortés, José Perez-García
The Lancet. Oncology. 2025-08-01
Understanding Associations Between Patient-Level Factors and Participation in a Breast Cancer Clinical Trial.
Nicole E Caston, Luqin Deng, Courtney P Williams, Emily B Levitan, Andres Azuero
Cancer Medicine. 2025-08-01
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELE...
Amy S Clark, Fengmin Zhao, Paula Klein, Alberto J Montero, Carla Falkson
Clinical Cancer Research. 2025-07-01

Journal Articles

Older Adults’ Preferences for Discussing Long-Term Life Expectancy: Results from a National Survey
Antonio C Wolff, Cynthia Boyd, Nancy L Schoenborn, Craig E Pollack, Annals of Family Medicine
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Aminah Jatoi, Antonio C Wolff, Harvey Jay Cohen, Rachel A Freedman, Gustav Magrinat, Julie Gralow, Gretchen Kimmick, Heidi D Klepin, Harold Burstein, Hyman Muss, Jeann..., Journal of the American Geriatrics Society

Lectures

The Practical Use of Molecular Profiling
2012 International Symposium, San Antonio, Texas, USA
The Practical Use of Molecular Profiling
San Antonio Breast Cancer Symposium, 2012 International Symposium, San Antonio, Texas, USA

Other

Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options
Wolff AC, Sikov WM
http://www.uptodate.com/contents/neoadjuvant-therapy-for-breast-cancer-rationale-pretreatment-evalua
UpToDate, Wolters Kluwer Health - 2012-09-17

Press Mentions

Researchers Aim to Adapt Metastatic Breast Cancer Therapy as Tumors ChangeJuly 2nd, 2025
SABCS Session Provides Clinical Implications of New Data and Practical TakeawaysJanuary 9th, 2025
View from the Trenches Panelists Share Thoughts on Translating SABCS® Presentations into PracticeDecember 15th, 2024
Join now to see all